Literature DB >> 30514135

HaNDL Syndrome: Case Report and Literature Review.

Amy Armstrong-Javors1, Kalpathy Krishnamoorthy1.   

Abstract

Headache and Neurologic Deficits with cerebrospinal fluid Lymphocytosis (HaNDL) syndrome is a rare stroke mimicker characterized by moderate to severe headache temporally associated with transient neurologic deficits, typically hemiparesis, hemisensory disturbance, and/or aphasia. Cerebrospinal fluid studies reveal a lymphocytosis and elevated protein. Episodes recur over a period no longer than 3 months. Here we describe the case of a 16-year-old boy who presented with 3 episodes of self-resolving neurologic deficits, papilledema on fundoscopic examination, and leptomeningeal enhancement on magnetic resonance imaging (MRI). We additionally review the 30 previously reported pediatric cases of HaNDL syndrome, with a focus on possible etiologic and pathophysiologic mechanisms of disease. The reported case and literature review highlight the benign episodic nature of this likely underrecognized syndrome as well as the higher than expected frequency of abnormal neuroimaging findings.

Entities:  

Keywords:  adolescents; headache; migraine; neuroimaging; stroke

Mesh:

Year:  2018        PMID: 30514135     DOI: 10.1177/0883073818811546

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  2 in total

1.  A cytotoxic lesion of the corpus callosum (CLOCC) in a patient with headache and neurological deficits with cerebrospinal fluid lymphocytosis (HaNDL): a hint for pathophysiology?

Authors:  Hüseyin Nezih Özdemir; Neşe Çelebisoy; Figen Gökçay; Ahmet Gökçay
Journal:  Acta Neurol Belg       Date:  2022-02-27       Impact factor: 2.396

Review 2.  HaNDL syndrome: a reversible cerebral vasoconstriction triggered by an infection? A case report and a case-based review.

Authors:  Giuseppe Fiamingo; Isabella Canavero; Matteo Gastaldi; Elisa Coloberti; Gabriele Buongarzone; Natascia Ghiotto; Ana Bacila; Alfredo Costa; Sabrina Ravaglia
Journal:  Eur J Med Res       Date:  2022-10-08       Impact factor: 4.981

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.